Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Researchers Discover Novel Cancer Immunotherapy Target

2015-11-20
|
Page View:

        Scientists from the Institut de recherches cliniques de Montreal (IRCM) led by André Veillette, M.D., have identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery (“DNAM-1 controls NK cell activation via an ITT-like motif”) is described in the Journal of Experimental Medicine.

   

        The researchers study natural killer (NK) cells, which are crucial to the immune system and protect the body by destroying cancer cells. The team is specifically interested in a protein called DNAM-1 that plays a key role in the elimination of cancer cells.


Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

   

        “We discovered the mechanism by which the DNAM-1 protein stimulates the function of NK cells and, thus, increases their capacity to eliminate cancer cells,” says Dr. Veillette, director of the molecular oncology research unit at the IRCM.

   

        The DNAM-1 protein is a receptor located at the surface of NK cells. It competes with other receptors that can interact with cancer cells, such as the TIGIT receptor that, on the contrary, reduces the efficiency of NK cells.

   

        “When the TIGIT receptor interacts with an infected cell, it prevents its interaction with the DNAM-1 protein, which, as a result, suppresses the function of NK cells and slows the immune system,” explains Dr. Veillette.

   

        Recent discoveries have led to the development of several immuno-oncology treatments, which use antibodies to improve the immune system’s natural function. Some of these antibodies, namely anti-CTLA-4 or anti-PD-1 antibodies, have already shown lasting benefits for many cancer patients.

   

    “Our results reveal how antibodies against TIGIT could become new therapies in immune-oncology,” adds Dr. Veillette. “These antibodies could improve the function of the DNAM-1 protein, thereby improving the ability of NK cells to destroy tumor cells. This type of therapy could have a significant impact on the next generation of cancer treatments.

Share:
Return
Relevant newsRelevant news